Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Blast Phase Refractory to Imatinib Mesylate (STI 571)

NCT00042003 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00042003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00042003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Blast Phase Refractory to Imatinib Mesylate (STI 571)
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2002
Completion date
Not reported
Enrollment
40
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia